Fintel reports that on May 28, 2025, Stifel downgraded their outlook for Vigil Neuroscience (NasdaqGS:VIGL) from Buy to Hold.

Vigil Neuroscience shares jumped nearly 250% Thursday after the Alzheimer's disease drug developer reached a deal to be ...

Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a ...

Fintel reports that on May 27, 2025, HC Wainwright & Co. downgraded their outlook for Vigil Neuroscience (NasdaqGS:VIGL) from ...

Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which ...

Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational ...

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

On Tuesday, Stifel analysts downgraded Vigil Neuroscience Inc (NASDAQ: VIGL) stock from a Buy to a Hold rating, concurrently reducing the price target from $11.00 to $8.00. This adjustment comes ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. About Vigil Neuroscience Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common ...

Sanofi SAN0.69%increase; green up pointing triangle said it entered an agreement to acquire Vigil Neuroscience VIGL 0.13%increase; green up pointing triangle for approximately $470 million ...